Lilly's Global COVID-19 Response Archives
January 31, 2023 Posted by: Eli Lilly and Company
News Releases, Resources and Multimedia - 2022
November
August
June
May
February
Lilly’s bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19 (February 11)
January
News Releases, Resources and Multimedia - 2021
December
Lilly’s statement on its monoclonal antibody therapies neutralization activity against the Omicron variant of concern (December 20)
Lilly's statement on the testing process of COVID-19 antibody therapies against the Omicron variant of concern (December 14)
November
September
Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19 (September 15)
August
Lilly’s statement on the reopening of distribution for COVID-19 antibody therapies in the U.S. (August 27)
July
June
May
April
GotMyShotCampaign.com, a community-wide effort supported by local government, health care, nonprofit and corporate partners to share facts about COVID-19 vaccines
March
February
Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19 (February 26)
January
Article: "Could monoclonal antibodies help in your COVID-19 treatment journey?" (January 15)
News Releases, Resources and Multimedia - 2020
December
Lilly to begin pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico (December 18)
November
Fourth iteration of COVID-19 treatment trial underway (November 25)
Article: "When the world called for help with COVID-19, we were ready" (November 10)
October
CEO Dave Ricks shares Lilly's principles of COVID-19 antibody therapy pricing and access (October 28)
Infographic: Lilly's access and affordability principles for our neutralizing antibodies (October 28)
Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 patients published in New England Journal of Medicine (October 28)
Infographic: Lilly's COVID-19 quest - key clinical trials for neutralizing antibodies (October 27)
Lilly statement regarding NIH's ACTIV-3 clinical trial (October 26)
Lilly statement on our commitment to quality manufacturing (October 20)
Lilly statement on the NIAID decision to pause enrollment in ACTIV-3 clinical trial (October 14)
Baricitinib has significant effect on recovery time, most effective in COVID-19 patients requiring oxygen (October 8)
Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs (October 7)
Article: "What does it take to manufacturing neutralizing antibodies?" (October 7)
September
STAT News: "Three lessons from COVID-19 on accelerating biopharma innovation," by Anne White, Lilly Oncology president (September 18)
Lilly and Amgen announce manufacturing collaboration for COVID-19 antibody therapies (September 17)
Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting (September 16)
Lilly's neutralizing antibodies and COVID-19 fact sheet (September 16)
August
July
Wall Street Journal video: "Scientists work to produce COVID-19 treatments under new conditions" (July 20)
Politico: "Four ways drug companies can ease racial disparities," by Lilly executives (July 20)
June
Lilly begins a Phase 3 clinical trial with baricitinib for hospitalized COVID-19 patients (June 15)
Lilly announces start of a Phase 1 study for its second potential COVID-19 antibody treatment (June 8)
Lilly begins world's first study of a potential COVID-19 antibody treatment in humans (June 1)
May
April
Indianapolis E-Learning Fund sends $1.5 million to Marion County districts and charter schools (April 27)
NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options (April 17)
Lilly begins clinical testing of therapies for COVID-19 (April 10)
Indianapolis E-Learning Fund launches with more than $2.6 million (April 8)
March
Lilly CEO Dave Ricks' letter to Americans who rely on Lilly insulin (March 30)
Lilly update on supply chain reliability and position on stockpiling (March 26)
46 organizations receive immediate grants from Central Indiana COVID-19 Economic Relief Fund (March 26)
Updates from Lilly on supply of medicines and insulin affordability (March 24)
Lilly provides update on clinical trial activities during COVID-19 pandemic (March 23)
Media teleconference regarding COVID-19 (March 18; audio only)
AbCellera and Lilly to co-develop antibody therapies for the treatment of COVID-19 (March 12)